• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Owens & Minor Launches ByramConnect Digital Health Platform for Diabetes and Other Chronic Health Conditions

    2/11/25 6:30:00 AM ET
    $OMI
    Medical Specialities
    Health Care
    Get the next $OMI alert in real time by email

    Now available as a free service exclusively to Byram Healthcare customers, ByramConnect powered by the Welldoc App combines digital health coaching, self-tracking, clinically relevant insights and education to support members with diabetes and associated chronic health conditions throughout their health journey.

    Byram Healthcare, a leader in home-based care and part of the Owens & Minor (NYSE:OMI) family, recently launched ByramConnectTM, a personalized digital health program powered by the Welldoc App®. Using the Welldoc App's advanced artificial intelligence capabilities, the program analyzes member data across six dimensions of health to help optimize outcomes for people with type 1 or type 2 diabetes and associated chronic conditions such as hypertension, weight management, and cardiovascular risk, providing Byram members with actionable insights and reports that can be shared with their providers and care teams.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250211464037/en/

    The ByramConnect platform offers Byram diabetes customers access to the Welldoc App, which provides their care teams a holistic view of their condition by combining patient-tracked health data and connected sources such as fitness trackers, blood glucose meters, continuous glucose monitors (CGMs), blood pressure monitors, scales, heart rate monitors and medical labs and pharmacies. (Photo: Business Wire)

    The ByramConnect platform offers Byram diabetes customers access to the Welldoc App, which provides their care teams a holistic view of their condition by combining patient-tracked health data and connected sources such as fitness trackers, blood glucose meters, continuous glucose monitors (CGMs), blood pressure monitors, scales, heart rate monitors and medical labs and pharmacies. (Photo: Business Wire)

    "Chronic health conditions like diabetes are complex and can have long-term health implications that require multiple supportive interventions over the course of a member's care journey," said Perry Bernocchi, EVP and CEO, Patient Direct, Owens & Minor. "We're proud to offer Byram members a clinically validated platform designed to help them achieve concrete goals, such as weight management and improved control over their diabetes, in addition to longer-lasting behavior changes that help support a lifetime of better overall health."

    ByramConnect powered by the Welldoc App is a U.S. Food and Drug Administration (FDA)-cleared class II software as a medical device (SaMD) intended for use by healthcare providers and adult patients with type 1 or type 2 diabetes*. In clinical studies, patients using the app saw improvements in several important measures related to their condition, including reduced (A1C), lower blood pressure and lower body weight.1-4 The ByramConnect platform offers Byram diabetes customers access to the Welldoc App, which provides their care teams a holistic view of their condition by combining patient-tracked health data and connected sources such as fitness trackers, blood glucose meters, continuous glucose monitors (CGMs), blood pressure monitors, scales, heart rate monitors and medical labs and pharmacies.

    Additional ByramConnect powered by the Welldoc App benefits include:

    • Digital coaching: personalized, AI-driven digital coaching providing real-time feedback and coaching based on a patient's unique data and trends
    • Diet and nutrition support: tracking, insights and guidance to help promote healthy eating habits, including meal planning and restaurant recommendations based on dietary requirements
    • GLP-1 medication support: support to help patients manage medications, monitor potential side-effects and track adherence over time
    • Reporting & insights: health reports with actionable insights based on the patient's unique data, patterns and trends that patients can share with their provider and care team
    • Mental wellbeing: guidance and reinforcement to help members manage overall wellbeing, including mood, sleep and anxiety

    *Welldoc Diabetes and Welldoc Diabetes Rx is an FDA-cleared medical device, intended for use by healthcare providers and their adult patients with type 1 or type 2 diabetes. For full labeling information, visit www.welldoc.com. The other Welldoc App products are non-FDA-cleared and intended to promote general wellness and education/self-management of various chronic disease states.

    ByramConnect powered by the Welldoc App can be used on any device and is available now as an included service exclusively for Byram diabetes customers at no additional charge. Byram customers will receive an invitation via email within the next couple of weeks with an exclusive access code allowing them to download the app from the Apple or Google Play App stores. More information about ByramConnect powered by the Welldoc App can be found at byramhealthcare.com/byram-connect-powered-by-welldoc.

    About Owens & Minor

    Owens & Minor, Inc. ((OMI) is a Fortune 500 global healthcare solutions company providing essential products and services that support care from the hospital to the home. For over 100 years, Owens & Minor and its affiliated brands, Apria®, Byram® and HALYARD*, have helped to make each day better for the patients, providers and communities we serve. Powered by more than 20,000 teammates worldwide, Owens & Minor delivers comfort and confidence behind the scenes so healthcare stays at the forefront. Owens & Minor exists because every day, everywhere, Life Takes Care™.

    For more information about Owens & Minor and our affiliated brands, visit owens-minor.com or follow us on LinkedIn and Instagram.

    *Registered Trademark or Trademark of O&M Halyard or its affiliates.

    About Byram

    Byram Healthcare ("Byram" or "Byram Healthcare Centers, Inc."), part of the Owens & Minor family, delivers the products, services and support patients need to help improve health outcomes and affordability of care in the home. Along with Apria, Byram Healthcare makes up the Owens & Minor Patient Direct business segment, which serves nearly three million patients each year and offers one of the broadest portfolios of products for chronic and acute conditions including diabetes, wound care, sleep health, respiratory care, urology and ostomy care. For more information, visit byramhealthcare.com.

    About Welldoc®

    Welldoc, a digital health leader revolutionizing cardiometabolic care, is integrating personalized, real-time and actionable insights into the daily lives of individuals living with cardiometabolic conditions, enabling improved health and outcomes. Welldoc's comprehensive digital health platform provides AI-powered digital coaching across pre-diabetes, diabetes, hypertension, heart failure and weight and obesity management, with integrated mental wellbeing and sleep support. The Welldoc App is an FDA-cleared digital health solution that guides individuals through the complicated journey of living with diabetes by enabling them to self-manage their care while enhancing connections to their healthcare team. For more information, visit www.welldoc.com.

    ______________

    1. Quinn, et al. Diabetes Care (2011).

    2. Kumbara et al. Diabetes Technology (2022).

    3. Welldoc Data on File.

    4. CDC. Workplace Health Promotion (2022).

    OMI-CORP

    OMI-IR

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250211464037/en/

    Media

    Stacy Law, Owens & Minor

    [email protected]

    Get the next $OMI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OMI

    DatePrice TargetRatingAnalyst
    7/19/2024$24.00 → $19.00Neutral → Buy
    Citigroup
    2/26/2024$24.00Market Perform
    Leerink Partners
    1/3/2024$21.00Equal Weight
    Barclays
    10/13/2022$52.00 → $18.00Buy → Neutral
    Citigroup
    10/12/2022$43.00 → $17.00Buy → Underperform
    BofA Securities
    10/12/2022$62.00 → $22.00Outperform → Neutral
    Robert W. Baird
    4/26/2022$55.00Buy
    Citigroup
    4/1/2022$43.00Neutral
    Credit Suisse
    More analyst ratings

    $OMI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Owens & Minor Reports First Quarter 2025 Financial Results

      Top-Line Growth Led by the Patient Direct Segment Patient Direct Operating Margin Expanded by 173 Basis Points Company Reaffirmed 2025 Financial Guidance Remain Actively Engaged in Potential Sale of Products & Healthcare Services Segment Owens & Minor, Inc. (NYSE:OMI) today reported financial results for the first quarter ended March 31, 2025. "Across the business we continued to see strong execution and progress towards our near and long-term strategies. Patient Direct delivered mid-single digit top-line growth with strong performance in nearly all therapy categories led by Diabetes and Sleep Supplies. The top-line growth combined with strong operational execution delivered mid-teen e

      5/8/25 6:30:00 AM ET
      $OMI
      Medical Specialities
      Health Care
    • Owens & Minor Announces First Quarter 2025 Earnings Release Date and Conference Call

      Owens & Minor, Inc. (NYSE:OMI) plans to release financial results for the first quarter of 2025 on Thursday, May 8, 2025, before trading begins on the New York Stock Exchange. The Company will host a conference call for investors and analysts at 8:00 a.m. EDT on the same day. Participants may access the call via the toll-free dial-in number at 1-888-300-2035, or the toll dial-in number at 1-646-517-7437. The conference ID access code is 1058917. All interested stakeholders are encouraged to access the simultaneous live webcast by visiting the Investor Relations page of the Owens & Minor website available at investors.owens-minor.com/events-and-presentations/. A replay of the webcast can b

      5/1/25 6:30:00 AM ET
      $OMI
      Medical Specialities
      Health Care
    • Owens & Minor Announces Major Innovations to Products & Healthcare Services Network

      Transformative investments in technology, automation and analytics capabilities will help improve supply chain visibility and resiliency for Products & Healthcare Services customers and lay the foundation for future innovations Owens & Minor, Inc. (NYSE:OMI) today announced important milestones in advancing the medical distribution capabilities of its Products & Healthcare Services (P&HS) business segment, which provides essential products and services to thousands of healthcare customers. These milestones are the result of recent company investments in new technology, automation and analytics capabilities geared specifically toward driving greater efficiencies for the P&HS segment and imp

      4/9/25 4:30:00 PM ET
      $OMI
      Medical Specialities
      Health Care

    $OMI
    Leadership Updates

    Live Leadership Updates

    See more
    • Owens & Minor Names Tammy Gomez EVP and Chief Human Resources Officer

      Gomez assumes leadership of Owens & Minor's people strategy with a focus on cultivating talent that supports company performance Owens & Minor, Inc. (NYSE:OMI), a leading global healthcare solutions company, today announced the appointment of Tammy Gomez as Executive Vice President & Chief Human Resources Officer, effective July 11, 2022. Gomez will report to Owens & Minor's President and Chief Executive Officer, Edward A. Pesicka, and be a member of the company's executive leadership team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220622005306/en/Owens & Minor names Tammy Gomez EVP and Chief Human Resources Officer, effect

      6/22/22 6:50:00 AM ET
      $OMI
      Medical Specialities
      Health Care

    $OMI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Coliseum Capital Management, Llc bought $3,073,750 worth of shares (410,000 units at $7.50) (SEC Form 4)

      4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)

      4/10/25 9:43:55 PM ET
      $OMI
      Medical Specialities
      Health Care
    • Large owner Coliseum Capital Management, Llc bought $4,291,218 worth of shares (528,356 units at $8.12) (SEC Form 4)

      4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)

      4/7/25 8:21:15 PM ET
      $OMI
      Medical Specialities
      Health Care
    • Large owner Coliseum Capital Management, Llc bought $27,386,158 worth of shares (2,893,412 units at $9.47) (SEC Form 4)

      4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)

      3/4/25 9:07:16 PM ET
      $OMI
      Medical Specialities
      Health Care

    $OMI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Owens & Minor Inc.

      SC 13G/A - OWENS & MINOR INC/VA/ (0000075252) (Subject)

      11/12/24 10:32:12 AM ET
      $OMI
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Owens & Minor Inc. (Amendment)

      SC 13G/A - OWENS & MINOR INC/VA/ (0000075252) (Subject)

      2/13/24 5:12:07 PM ET
      $OMI
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Owens & Minor Inc. (Amendment)

      SC 13G/A - OWENS & MINOR INC/VA/ (0000075252) (Subject)

      2/12/24 5:29:41 PM ET
      $OMI
      Medical Specialities
      Health Care

    $OMI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Owens & Minor upgraded by Citigroup with a new price target

      Citigroup upgraded Owens & Minor from Neutral to Buy and set a new price target of $19.00 from $24.00 previously

      7/19/24 7:41:01 AM ET
      $OMI
      Medical Specialities
      Health Care
    • Leerink Partners initiated coverage on Owens & Minor with a new price target

      Leerink Partners initiated coverage of Owens & Minor with a rating of Market Perform and set a new price target of $24.00

      2/26/24 8:10:20 AM ET
      $OMI
      Medical Specialities
      Health Care
    • Barclays initiated coverage on Owens & Minor with a new price target

      Barclays initiated coverage of Owens & Minor with a rating of Equal Weight and set a new price target of $21.00

      1/3/24 8:05:34 AM ET
      $OMI
      Medical Specialities
      Health Care

    $OMI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Rollins Carissa was granted 28,914 shares, increasing direct ownership by 116% to 53,902 units (SEC Form 4)

      4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)

      5/16/25 6:11:21 PM ET
      $OMI
      Medical Specialities
      Health Care
    • Director Kline Teresa L. was granted 28,914 shares, increasing direct ownership by 115% to 54,125 units (SEC Form 4)

      4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)

      5/16/25 6:10:49 PM ET
      $OMI
      Medical Specialities
      Health Care
    • Director Henkel Robert J was granted 28,914 shares, increasing direct ownership by 60% to 77,412 units (SEC Form 4)

      4 - OWENS & MINOR INC/VA/ (0000075252) (Issuer)

      5/16/25 6:10:08 PM ET
      $OMI
      Medical Specialities
      Health Care

    $OMI
    SEC Filings

    See more
    • Owens & Minor Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - OWENS & MINOR INC/VA/ (0000075252) (Filer)

      5/16/25 8:30:34 AM ET
      $OMI
      Medical Specialities
      Health Care
    • SEC Form 10-Q filed by Owens & Minor Inc.

      10-Q - OWENS & MINOR INC/VA/ (0000075252) (Filer)

      5/8/25 4:05:35 PM ET
      $OMI
      Medical Specialities
      Health Care
    • Owens & Minor Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - OWENS & MINOR INC/VA/ (0000075252) (Filer)

      5/8/25 6:35:09 AM ET
      $OMI
      Medical Specialities
      Health Care

    $OMI
    Financials

    Live finance-specific insights

    See more
    • Owens & Minor Reports First Quarter 2025 Financial Results

      Top-Line Growth Led by the Patient Direct Segment Patient Direct Operating Margin Expanded by 173 Basis Points Company Reaffirmed 2025 Financial Guidance Remain Actively Engaged in Potential Sale of Products & Healthcare Services Segment Owens & Minor, Inc. (NYSE:OMI) today reported financial results for the first quarter ended March 31, 2025. "Across the business we continued to see strong execution and progress towards our near and long-term strategies. Patient Direct delivered mid-single digit top-line growth with strong performance in nearly all therapy categories led by Diabetes and Sleep Supplies. The top-line growth combined with strong operational execution delivered mid-teen e

      5/8/25 6:30:00 AM ET
      $OMI
      Medical Specialities
      Health Care
    • Owens & Minor Announces First Quarter 2025 Earnings Release Date and Conference Call

      Owens & Minor, Inc. (NYSE:OMI) plans to release financial results for the first quarter of 2025 on Thursday, May 8, 2025, before trading begins on the New York Stock Exchange. The Company will host a conference call for investors and analysts at 8:00 a.m. EDT on the same day. Participants may access the call via the toll-free dial-in number at 1-888-300-2035, or the toll dial-in number at 1-646-517-7437. The conference ID access code is 1058917. All interested stakeholders are encouraged to access the simultaneous live webcast by visiting the Investor Relations page of the Owens & Minor website available at investors.owens-minor.com/events-and-presentations/. A replay of the webcast can b

      5/1/25 6:30:00 AM ET
      $OMI
      Medical Specialities
      Health Care
    • Owens & Minor Reports Fourth Quarter & Full Year Financial Results and Announces Sale Process Underway for Products & Healthcare Services Segment

      Total Debt Reduction of $244 Million in 2024, Capping a Two-Year Total Debt Reduction of $647 Million 2025 Guidance Midpoint Indicates Double-Digit Adjusted EBITDA & Adjusted EPS Growth, and Improving Cash Flow Active Discussions Well Underway Regarding Potential Sale of Products & Healthcare Services (P&HS) Segment Board of Directors Authorizes Share Repurchase Program of Up to $100 Million Owens & Minor, Inc. (NYSE:OMI) today reported financial results for the fourth quarter and year ended December 31, 2024. "We are pleased with the progress that we have made against the strategy as outlined at our Investor Day in December 2023. As a reminder, we committed to optimizing our Prod

      2/28/25 6:30:00 AM ET
      $OMI
      Medical Specialities
      Health Care